# US 2002/0058632 A1 · Medicament and therapeutical method for treating idiopathic asthenozoospermia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058632 A1
- Document ID: US20020058632A1
- Status: Published application
- Kind: A1
- Application number: 10/003,281
- Filed: 2001-12-06
- Published: 2002-05-16
- Earliest claimed: 1997-12-01
- Assignees: Sigma-Tau HealthScience S.p.A.
- Inventors: Claudio Cavazza
- Web page: https://patentgrep.com/patent/US20020058632A1

## CPC

- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A therapeutical method is disclosed for treating idiopathic asthenozoospermia which comprises orally or parenterally administering to a patient in need thereof a combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in substantially equimolar amouts.

## Claims

### Claim 1

An orally or parenterally administrable combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in a molar ratio ranging from 1.5:1 to 1:1.5.

### Claim 2 (depends on 1)

The preparation of claim 1, wherein said molar ratio is 1:1.

### Claim 3 (depends on 1)

The preparation of claim 1 in unit dosage form comprising from 0.33 g to 0.22 g of L-carnitine inner salt and from 0.28 g to 0.42 g of acetyl L-carnitine or equimolar amounts of the pharmacologically acceptable salts thereof.

### Claim 4 (depends on 2)

The preparation of claim 2 in unit dosage form comprising 0.22 g of L-carnitine inner salt and 0.28 g of acetyl L-carnitine inner salt or equimolar amounts of the pharmacologically acceptable salts thereof.

### Claim 5 (depends on 1)

The preparation of claim 1 wherein the pharmacologically acceptable salt of L-carnitine and acetyl L-carnitine is selected form the group comprising: chloride; bromide; iodide; aspartate, particularly acid aspartate; citrate, particularly acid citrate; tartrate; phosphate, particularly acid phosphate; fumarate, particularly acid fumarate;
glycerophosphate; glucose phosphate; lactate; maleate, particularly acid maleate; orotate; oxalate, particularly acid oxalate; sulphate, particularly acid sulphate; trichloroacetate; trifluoro acetate and methanesulphonate.

### Claim 6

A therapeutical method for treating idiopathic asthenozoospermia which comprises orally or parenterally administering to a patient in need thereof a combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in a molar ratio ranging from 1.5:1 to 1:1.5.

### Claim 7 (depends on 6)

The method of claim 6, wherein said molar ratio is 1:1.

### Claim 8 (depends on 6)

The method of claim 6 which comprises orally or parenterally administering to said patients in a single or multiple dose administration regimen a total amount of 0.60-1.0 g/day of L-carnitine inner salt and 0.80-1.3 g/day of acetyl L-carnitine inner salt or equimolar amounts of the pharmacologically acceptable salts thereof.
